Key facts
- Notable investors include CMB International Capital, Chunjia Capital, GF Securities, Guangdong Yigao Zhihui Equity Investment Fund Management, Nanjing Meitiansheng Venture Capital Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Vertexyn Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Vertexyn Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vertexyn Bio
Manufacturer of bio-based raw materials aims to advance engineered biotechnology and promote sustainable development. The company's offerings feature high-value natural bio-based raw materials for pharmaceuticals, daily care, functional foods, animal and plant nutrition, and pesticides, supported by expertise in gene data mining, strain engineering, large-scale fermentation, and product application development, enabling healthier living and greener manufacturing worldwide.
- Sector
- Healthcare
- HQ
- Xuzhou, China
- Founded
- 2019
- Website
- vertexynbio.com/
- Ownership
- Privately Held (backing)
Vertexyn Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vertexyn Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vertexyn Bio in its N-PORT filings yet. We sweep new filings monthly.